Form 4: Grace Therapeutics VP Acquires Stock Options

Carrie D'Andrea, VP of Clinical Operations at Grace Therapeutics, acquired stock options for 30,000 shares of common stock.

Summary

• Carrie D'Andrea, VP of Clinical Operations at Grace Therapeutics, acquired stock options.
• The transaction occurred on April 14, 2025.
• The stock options grant the right to buy 30,000 shares of common stock at an exercise price of $2.08 per share.
• The options vest quarterly over a 3-year period, contingent upon continuous service.
• The options expire on April 14, 2035.
• A Power of Attorney was executed on April 9, 2025, granting certain individuals the authority to act on D'Andrea's behalf for SEC filings.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine executive compensation disclosure. The grant itself is a positive incentive for the executive, but doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, aligning their interests with the company's success.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies. Stock options are a common form of compensation to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules, such as the quarterly vesting over 3 years described, are also standard practice to encourage long-term commitment.

Stakeholder Impact

• The stock option grant could potentially incentivize the VP of Clinical Operations to improve company performance, benefiting shareholders.

Key Dates

Keywords

stock options, Form 4, Grace Therapeutics, insider trading, beneficial ownership, securities, GRCE, D'Andrea